Ki-67 Proliferative Marker in Thyroid Lesions

Introduction: Approximately 5 percent of thyroid cancers happen in all thyroid nodules, regardless of their size. PTC is the most prevalent type of thyroid cancer in all thyroid cancers. Although it is hard to distinguish PTC from benign papillary hyperplasia of the thyroid gland on the basis of its morphology, it is essential to distinguish benign ones from malignant ones for early therapy and better patient management. Although the diagnostic and prognostic values of Ki-67/MIB-1 in thyroid cancer stay uncertain, it has been noted that Ki-67/MIB-1 has an impact.

Materials and Method: 60 gross samples have been taken for research. These biopsy samples were regularly fixed in 10% formalin and processed in paraffin wax. Five micron dense parts were sliced and drawn for research and hematoxylin and eosin staining of the parts was performed. Histopathological examination of these segments has been carried out. The immunohistochemistry survey using Ki-67 monoclonal antibody as a proliferation marker was conducted in 60 cases. The current survey was conducted to determine the function of ki-67 in distinct kinds of neoplastic and non-neoplastic thyroid lesions.

Results: Mean Ki67 LI values in our research were 14.12 ± 2.29, 61.42 ± 3.77 and 34.90 ± 3.49 and 18.60 ± 1.96 for PTC, FTC, FTA and NG, respectively. In this research, numerous group comparisons were made using the Bonferroni post-hoc test, and Ki-67 values were discovered to be statistically important among all thyroid lesions.

Conclusion: Although the Ki-67 marker is costly, it was discovered to be very simple to conduct and to get better outcomes. It is therefore found that the Ki-67 marker is suggested to be used in instances of dubious capsular and/or vascular invasion and follicular lesions with questionable nuclear characteristics.